With 1.54 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.28 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $50.525 whereas the lowest price it dropped to was $48.66. The 52-week range on GH shows that it touched its highest point at $52.92 and its lowest point at $20.14 during that stretch. It currently has a 1-year price target of $58.71. Beta for the stock currently stands at 1.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GH was up-trending over the past week, with a rise of 9.39%, but this was up by 20.06% over a month. Three-month performance surged to 17.50% while six-month performance rose 34.98%. The stock gained 72.61% in the past year, while it has gained 63.96% so far this year. A look at the trailing 12-month EPS for GH yields -3.38 with Next year EPS estimates of -2.33. For the next quarter, that number is -0.72. This implies an EPS growth rate of 22.64% for this year and 15.52% for next year. EPS is expected to grow by 21.96% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -33.61%.
Float and Shares Shorts:
At present, 123.65 million GH shares are outstanding with a float of 117.62 million shares on hand for trading. On 2025-05-15, short shares totaled 9.12 million, which was 736.0 higher than short shares on 1744675200. In addition to Dr. Helmy Eltoukhy Ph.D. as the firm’s Co-Founder, Co-CEO & Chairman, Dr. AmirAli Talasaz Ph.D. serves as its Co-CEO & Director.
Institutional Ownership:
Through their ownership of 0.97573996 of GH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, GH reported revenue of $203471000.0 and operating income of -$111041000.0. The EBITDA in the recently reported quarter was -$83842000.0 and diluted EPS was -$0.77.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GH since 13 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GH analysts setting a high price target of 70.0 and a low target of 47.0, the average target price over the next 12 months is 59.43455. Based on these targets, GH could surge 39.75% to reach the target high and fall by -6.17% to reach the target low. Reaching the average price target will result in a growth of 18.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.28598 being high and -$3.52199 being low. For GH, this leads to a yearly average estimate of -$3.41306.
